Closing the GLP-1 Coverage Gap: Q&A with Susan Thomas Mike Hollan , Susan Thomas Key Takeaways Formulary decisions commonly restrict access to T2D and weight loss, creating coverage blind spots as GLP-1 trials mature across broader cardiometabolic and organ-protection indications
If you normally inject on Friday mornings but need to move one dose to Thursday evening, that single adjustment poses no safety concern
This purified phosphatidylcholine delivery system shields the fragile peptide bonds of the glutathione from the harsh digestive acids and enzymatic degradation of the stomach and intestines
Whether the coaching program delivers on its description is worth asking about directly during intake - specifically, what format sessions take, how often they occur, and what happens if your assigned coach is unavailable
A review of head-to-head clinical trials comparing key outcomes of using GLP-1RAs (dulaglutide, exenatide BD, exenatide QW, liraglutide or lixisenatide) with those of using DPP-IV (sitagliptin), SU (glimepiride
Virology 282 : 2637